Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients

Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. The aim of this...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and diagnostic research 2017-03, Vol.11 (3), p.OC09-OC12
Main Authors: Soleimani, Akbar, Mobedi, Zahra, Al-E-Rasul, Maryam, Sharifi, Abolghasem, Vardanjani, Abdolrahim Kazemi
Format: Article
Language:English
Subjects:
human leukocyte antigen
rheumatic diseases
rheumatoid factor
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c416t-5b5faff96a5d37569fd8e9523cd571c334a8b087e1be8773c0920e1e555c3af73
cites
container_end_page OC12
container_issue 3
container_start_page OC09
container_title Journal of clinical and diagnostic research
container_volume 11
creator Soleimani, Akbar
Mobedi, Zahra
Al-E-Rasul, Maryam
Sharifi, Abolghasem
Vardanjani, Abdolrahim Kazemi
description Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. The aim of this study was to investigate the effects of gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p
doi_str_mv 10.7860/JCDR/2017/8567.9436
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d522d5441a4b4aebbdabe0f380d5200c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d522d5441a4b4aebbdabe0f380d5200c</doaj_id><sourcerecordid>1899792546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-5b5faff96a5d37569fd8e9523cd571c334a8b087e1be8773c0920e1e555c3af73</originalsourceid><addsrcrecordid>eNo9kctu1DAUhiMEokPhCZCQl2zS8SW242XIFDpoJKoBpO4sxz6mrjLJYDuIeQDem4QpXR3pP_9l8RXFW4KvZC3w-nO72a8pJnJdcyGvVMXEs2KFlWSlxOruebGitFKlrOndRfEqpQeMhRBMvCwuaM0JqahYFX-uvQeb0ehRM-RQtifbB4vakOPU92EwGRy6hWMODpAZHLrZNeVm_4Ggr1OXT0dIaBxQOzuDNT3ahAQmAWpsDr9CPqHt4OA3CgPa38N0MHkMDjUx38eQQ0K3JgcYcnpdvPCmT_Dm8V4W3z9ef2tvyt2XT9u22ZW2IiKXvOPeeK-E4Y5JLpR3NShOmXVcEstYZeoO1xJIB7WUzGJFMRDgnFtmvGSXxfbc60bzoI8xHEw86dEE_U8Y4w9tYg62B-04pY5XFTFVVxnoOmc6wJ7VeP5gbOeu9-euYxx_TpCyPoRkoe_NAOOUNKmVkorySsxWdrbaOKYUwT9NE6wXlnphqReWemGpF5Zz6t3jwNQdwD1l_sNjfwFwjZst</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899792546</pqid></control><display><type>article</type><title>Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients</title><source>PubMed Central</source><creator>Soleimani, Akbar ; Mobedi, Zahra ; Al-E-Rasul, Maryam ; Sharifi, Abolghasem ; Vardanjani, Abdolrahim Kazemi</creator><creatorcontrib>Soleimani, Akbar ; Mobedi, Zahra ; Al-E-Rasul, Maryam ; Sharifi, Abolghasem ; Vardanjani, Abdolrahim Kazemi</creatorcontrib><description>Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. The aim of this study was to investigate the effects of gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p&lt;0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.</description><identifier>ISSN: 2249-782X</identifier><identifier>EISSN: 0973-709X</identifier><identifier>DOI: 10.7860/JCDR/2017/8567.9436</identifier><identifier>PMID: 28511426</identifier><language>eng</language><publisher>India: JCDR Research and Publications Private Limited</publisher><subject>human leukocyte antigen ; rheumatic diseases ; rheumatoid factor</subject><ispartof>Journal of clinical and diagnostic research, 2017-03, Vol.11 (3), p.OC09-OC12</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-5b5faff96a5d37569fd8e9523cd571c334a8b087e1be8773c0920e1e555c3af73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28511426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soleimani, Akbar</creatorcontrib><creatorcontrib>Mobedi, Zahra</creatorcontrib><creatorcontrib>Al-E-Rasul, Maryam</creatorcontrib><creatorcontrib>Sharifi, Abolghasem</creatorcontrib><creatorcontrib>Vardanjani, Abdolrahim Kazemi</creatorcontrib><title>Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients</title><title>Journal of clinical and diagnostic research</title><addtitle>J Clin Diagn Res</addtitle><description>Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. The aim of this study was to investigate the effects of gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p&lt;0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.</description><subject>human leukocyte antigen</subject><subject>rheumatic diseases</subject><subject>rheumatoid factor</subject><issn>2249-782X</issn><issn>0973-709X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9kctu1DAUhiMEokPhCZCQl2zS8SW242XIFDpoJKoBpO4sxz6mrjLJYDuIeQDem4QpXR3pP_9l8RXFW4KvZC3w-nO72a8pJnJdcyGvVMXEs2KFlWSlxOruebGitFKlrOndRfEqpQeMhRBMvCwuaM0JqahYFX-uvQeb0ehRM-RQtifbB4vakOPU92EwGRy6hWMODpAZHLrZNeVm_4Ggr1OXT0dIaBxQOzuDNT3ahAQmAWpsDr9CPqHt4OA3CgPa38N0MHkMDjUx38eQQ0K3JgcYcnpdvPCmT_Dm8V4W3z9ef2tvyt2XT9u22ZW2IiKXvOPeeK-E4Y5JLpR3NShOmXVcEstYZeoO1xJIB7WUzGJFMRDgnFtmvGSXxfbc60bzoI8xHEw86dEE_U8Y4w9tYg62B-04pY5XFTFVVxnoOmc6wJ7VeP5gbOeu9-euYxx_TpCyPoRkoe_NAOOUNKmVkorySsxWdrbaOKYUwT9NE6wXlnphqReWemGpF5Zz6t3jwNQdwD1l_sNjfwFwjZst</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Soleimani, Akbar</creator><creator>Mobedi, Zahra</creator><creator>Al-E-Rasul, Maryam</creator><creator>Sharifi, Abolghasem</creator><creator>Vardanjani, Abdolrahim Kazemi</creator><general>JCDR Research and Publications Private Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20170301</creationdate><title>Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients</title><author>Soleimani, Akbar ; Mobedi, Zahra ; Al-E-Rasul, Maryam ; Sharifi, Abolghasem ; Vardanjani, Abdolrahim Kazemi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-5b5faff96a5d37569fd8e9523cd571c334a8b087e1be8773c0920e1e555c3af73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>human leukocyte antigen</topic><topic>rheumatic diseases</topic><topic>rheumatoid factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soleimani, Akbar</creatorcontrib><creatorcontrib>Mobedi, Zahra</creatorcontrib><creatorcontrib>Al-E-Rasul, Maryam</creatorcontrib><creatorcontrib>Sharifi, Abolghasem</creatorcontrib><creatorcontrib>Vardanjani, Abdolrahim Kazemi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of clinical and diagnostic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soleimani, Akbar</au><au>Mobedi, Zahra</au><au>Al-E-Rasul, Maryam</au><au>Sharifi, Abolghasem</au><au>Vardanjani, Abdolrahim Kazemi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients</atitle><jtitle>Journal of clinical and diagnostic research</jtitle><addtitle>J Clin Diagn Res</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>11</volume><issue>3</issue><spage>OC09</spage><epage>OC12</epage><pages>OC09-OC12</pages><issn>2249-782X</issn><eissn>0973-709X</eissn><abstract>Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. The aim of this study was to investigate the effects of gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p&lt;0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.</abstract><cop>India</cop><pub>JCDR Research and Publications Private Limited</pub><pmid>28511426</pmid><doi>10.7860/JCDR/2017/8567.9436</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2249-782X
ispartof Journal of clinical and diagnostic research, 2017-03, Vol.11 (3), p.OC09-OC12
issn 2249-782X
0973-709X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d522d5441a4b4aebbdabe0f380d5200c
source PubMed Central
subjects human leukocyte antigen
rheumatic diseases
rheumatoid factor
title Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A52%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Anti-Cyclic%20Citrullinated%20Peptide%20and%20HLA-DRB1%20Subtypes%20on%20Clinical%20Disease%20Activity%20Index%20in%20Rheumatoid%20Arthritis%20Patients&rft.jtitle=Journal%20of%20clinical%20and%20diagnostic%20research&rft.au=Soleimani,%20Akbar&rft.date=2017-03-01&rft.volume=11&rft.issue=3&rft.spage=OC09&rft.epage=OC12&rft.pages=OC09-OC12&rft.issn=2249-782X&rft.eissn=0973-709X&rft_id=info:doi/10.7860/JCDR/2017/8567.9436&rft_dat=%3Cproquest_doaj_%3E1899792546%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-5b5faff96a5d37569fd8e9523cd571c334a8b087e1be8773c0920e1e555c3af73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1899792546&rft_id=info:pmid/28511426&rfr_iscdi=true